Detalhe da pesquisa
1.
A learning health system approach to the COVID-19 pandemic: System-wide changes in clinical practice and 30-day mortality among hospitalized patients.
Learn Health Syst
; 6(3): e10304, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35860323
2.
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
JAMA Netw Open
; 5(4): e226920, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35412625
3.
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.
Contemp Clin Trials
; 113: 106652, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34896293
4.
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
Contemp Clin Trials
; 119: 106822, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35697146
5.
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
JAMA Netw Open
; 5(7): e2220957, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35834252
6.
Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment.
J Am Coll Emerg Physicians Open
; 2(5): e12550, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34568870
7.
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
Trials
; 22(1): 363, 2021 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34034784